Yellowbird Diagnostics Begins Dosing First Patients in Phase 1 Trial of NeuCavis™

Yellowbird Diagnostics Advances Metabolic Imaging with NeuCaVis™ Phase I Trial

On April 15, 2026, Yellowbird Diagnostics Inc. announced the successful initiation of its Phase I clinical trial for NeuCaVis™, a groundbreaking metabolic PET imaging agent engineered to enhance the visualization of inflammation within the body. This innovative approach targets fructose metabolism, a pathway closely linked to inflammatory activities that can lead to various serious health conditions such as cardiovascular diseases, chronic inflammatory disorders, neuroinflammation, and cancer.

The Phase I trial, which is open-label and involves single dosing, is being conducted at the University of Ottawa Heart Institute, under the guidance of Dr. Benjamin Chow. This study aims to assess the safety, tolerability, and dosimetry of NeuCaVis™ in healthy volunteers, marking a significant milestone in the field of molecular imaging.

Innovative Inflammation Imaging Technology

Inflammation is a driving force behind many prevalent diseases; however, visualizing it precisely has posed a challenge in medical imaging. NeuCaVis™ is heralded as a first-in-class PET tracer that facilitates the direct imaging of fructose metabolism, thereby providing a more specific signal indicative of inflammatory activity in the body. Early preclinical and clinical data suggest that NeuCaVis™ displays minimal background signal, focusing uptake primarily in areas of active inflammation. This targeted approach could lead to enhanced diagnostic clarity, enabling better clinical decision-making.

Adam Shuhendler, Chief Scientific Officer and Co-Founder of Yellowbird Diagnostics, described the dosing of the first patients as a pivotal achievement for the company and the molecular imaging sector. He emphasized the company's commitment to transcending the limitations of traditional PET imaging technologies, aiming to furnish clinicians and patients with clearer, more actionable insights into health conditions.

Adding to this sentiment, Dr. Benjamin Chow commented on the pressing requirement for more precise imaging techniques for inflammation in cardiology. Early observations from the study indicate that NeuCaVis™ holds the potential to boost diagnostic confidence, thereby improving management strategies for patients.

About Yellowbird Diagnostics

Yellowbird Diagnostics is an Ottawa-based biotechnology company focused on developing next-generation metabolic imaging agents designed to detect diseases earlier and enhance clinical decision-making. The company’s leadership team comprises Co-Founders Nicholas D. Calvert (CEO), Alexia Kirby (COO), and Adam Shuhendler (CSO), with Michael Gottlieb serving as Executive Board Chair.

The Phase I program for NeuCaVis™ has garnered support from numerous stakeholders, including the Brain and Heart Interconnectome, Capital BioVentures, FACIT, Canadian Medical Isotope Ecosystem, Ontario Brain Institute, University of Ottawa Heart Institute, and Yellowbird’s investor base. This collaboration underscores the broad interest and support for advancing innovative imaging technologies aimed at improving patient outcomes through better diagnostic capabilities.

Overall, the successful dosing in the Phase I trial marks a new frontier in inflammation imaging and positions Yellowbird Diagnostics at the forefront of medical imaging innovation. As the trial progresses, there are high expectations for NeuCaVis™ to transform how inflammatory conditions are diagnosed and managed in clinical settings.